A Multicenter, International, Prospective, Non-interventional, Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting (HYRISS)

NCT05633771 ACTIVE_NOT_RECRUITING

An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.

Details

Lead sponsor	Sandoz
Status	ACTIVE_NOT_RECRUITING
Enrolment	562
Start date	2023-02-16
Completion	2026-12

Conditions

• Inflammatory Bowel Disease

Interventions

• Hyrimoz

Primary outcomes

• Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation — Up to 6 months
  Assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation

Countries

Belgium, France